Descontinuación del esteroide inhalado en pacientes con enfermedad pulmonar obstructiva crónica moderada a severa no aumenta el riesgo de exacerbaciones

Carlos Andrés Celis Preciado, MD.

doi:10.30789/rcneumologia.v26.n4.2014.9

Descontinuación del esteroide inhalado en pacientes con enfermedad pulmonar obstructiva crónica moderada a severa no aumenta el riesgo de exacerbaciones

Descontinuación del esteroide inhalado en pacientes con enfermedad pulmonar obstructiva crónica moderada a severa no aumenta el riesgo de exacerbaciones

Publicado 2016-05-24

Abrir | Descargar

PDF FLIP

Número

Vol. 26 Núm. 4 (2014)

Sección

Clubes de revista

Cómo citar

Descontinuación del esteroide inhalado en pacientes con enfermedad pulmonar obstructiva crónica moderada a severa no aumenta el riesgo de exacerbaciones.

rev. colomb. neumol. [Internet]. 2016 May 24 [cited 2024 Nov. 23];26(4). Disponible en: https://doi.org/10.30789/rcneumologia.v26.n4.2014.9

DOI

https://doi.org/10.30789/rcneumologia.v26.n4.2014.9

Dimensions

PlumX

Licencia

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Carlos Andrés Celis Preciado, MD.

Pontificia Universidad Javeriana

Mostrar biografía de los autores

Carlos Andrés Celis Preciado, MD.,

Internista, Neumólogo, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

Visitas del artículo 453 | Visitas PDF 598

Descargas

Los datos de descarga todavía no están disponibles.

From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Disponible en: http://www.goldcopd.org/ Fecha de acceso: 10/09/14.
Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol. 2014;78(2):282-300.
Halpin DM, Quint JK. The WISDOM of inhaled corticosteroids in COPD. Thorax. 2014;69(12):1071-2.
Agustí A. Inhaled steroids in COPD: Reasons for a debate. Rev Port Pneumol (2006). 2015;21(4):175-7.
Laniado-Laborín R. Discontinuing inhaled steroids might not be safe in severe COPD cases. Evid Based Med. 2015;20(2):57.
Stanbrook MB. ACP journal club. For preventing exacerbations of COPD, withdrawal of inhaled glucocorticoids was noninferior to continuation. Ann Intern Med. 2015;162(6):JC5.
Balkissoon R. Journal club. J COPD F. 2015; 2(1): 85-90.
Rodriguez Roisin R, Arismendi E. Inhaled corticosteroids withdrawal in severe patients with chronic obstructive pulmonary disease: a wisdom decision? Arch Bronconeumol. 2015;51(2):57-8.
Cazzola M, Rogliani P, Matera MG. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015. [Epub ahead of print].
Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548-56.
Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD
patients (OPTIMO). Respir Res. 2014;15:77.
Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Thorax. 2005;60(6):480-7.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2015;191(2):141-8.
Ni S, Fu Z, Zhao J, Liu H. Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a metaanalysis. J Thorac Dis. 2014;6(7):971-8.
Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-62.
Dong YH, Chang CH, Lin Wu FL, Shen LJ, Calverley PM, Löfdahl CG, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(6):1286-97.
Gläser S, Krüger S, Merkel M, Bramlage P, Herth FJ. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration. 2015;89(3):253-64.
Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14(7):983-90.
Battaglia S, Cardillo I, Lavorini F, Spatafora M, Scichilone N. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging. 2014;31(11):787-96.
Agusti A, Fabbri LM. Inhaled steroids in COPD: when should they be used? Lancet Respir Med. 2014;2(11):869-71.